Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Diabetic Nephropathy

Interventions

DRUG: Atrasentan
DRUG: Placebo

Sponsor

AbbVie (prior sponsor, Abbott)